Omrix Biopharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

Global Markets Direct, November 2010, Pages: 40

Omrix Biopharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Omrix Biopharmaceuticals, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Omrix Biopharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Omrix Biopharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Omrix Biopharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Omrix Biopharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Omrix Biopharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Omrix Biopharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Omrix Biopharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Omrix Biopharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Omrix Biopharmaceuticals, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
Omrix Biopharmaceuticals, Inc. Snapshot
Omrix Biopharmaceuticals, Inc. Overview
Key Information
Key Facts
Omrix Biopharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Omrix Biopharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Omrix Biopharmaceuticals, Inc. – Pipeline Products Glance
Omrix Biopharmaceuticals, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Omrix Biopharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Omrix Biopharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Omrix Biopharmaceuticals, Inc. – Drug Profiles
HBIG
Product Description
Mechanism of Action
R&D Progress
Omr-IgG-am
Product Description
Mechanism of Action
R&D Progress
WNIG
Product Description
Mechanism of Action
R&D Progress
HT-VIG
Product Description
Mechanism of Action
R&D Progress
Omrix Biopharmaceuticals, Inc. – Pipeline Analysis
Omrix Biopharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Omrix Biopharmaceuticals, Inc. – Pipeline Products by Route of Administration
Omrix Biopharmaceuticals, Inc. – Pipeline Products by Molecule Type
Omrix Biopharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Omrix Biopharmaceuticals, Inc. - Key Manufacturing Facilities
Recent Developments
Sep 08, 2010: Octapharma Initiates Phase II/III Study Of Intravenous Immunoglobulin Preparation For Treatment Of Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Financial Deals Landscape
Omrix Biopharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2010
Omrix Biopharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2010
Omrix Biopharmaceuticals, Inc., Deals Summary, 2004 to YTD 2010
Omrix Biopharmaceuticals, Inc. Detailed Deal Summary
Acquisition
Johnson & Johnson Completes Acquisition Of Omrix Biopharmaceuticals
Private Equity
Savient Pharmaceuticals Sells Its Stake In Omrix Biopharmaceuticals To Catalyst Investments
Equity Offering
Omrix Biopharmaceuticals Completes Public Offering Of $55 Million
Omrix Biopharmaceuticals Completes Initial Public Offering Of $39.53 Million
Omrix Biopharmaceuticals Completes Private Placement Of $5 Million
Omrix Biopharmaceuticals Signs An Agreement With NIAID
Omrix Biopharmaceuticals Enters Into An Agreement With FFF Enterprises
Omrix Biopharmaceuticals Enters Into Co-Marketing Agreement With American Red Cross Plasma Services
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Charter Schools - Global Outlook
• eLEARNING - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• North America – Smart Weapons Markets and Technologies Outlook – 2013-2020
• Sports and Fitness Nutrition - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Private Tutoring - Global Strategic Business Report
• Defense Robotics - Global Strategic Business Report
• The Worldwide Industry & Market Opportunities and forecasts to 2014 for Microwaves Global Military & Space-Related Systems